HBHA vaccination may require both Th1 and Th17 immune responses to protect mice against tuberculosis

Vaccine

Volumn 32, Issue 47, 2014, Pages 6240-6250

  Verwaerde, Claudie ^a,b   Debrie, Anne Sophie ^a,b   Dombu, Christophe ^b   Legrand, Damien ^a   Raze, Dominique ^a,b   Lecher, Sophie ^a,b   Betbeder, Didier ^b   Locht, Camille ^a,b  

^a INSERM U1019   (France)

^b UNIV LILLE   (France)

Author keywords

CpG; HBHA; Nanoparticle; Th17 response; Tuberculosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; HEPARIN BINDING HAEMAGGLUTININ; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 5; NANOPARTICLE; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; CPG ODN 1826; HEPARIN-BINDING HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; LECTIN; LIPID A; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNE RESPONSE; LUNG; MOUSE; NONHUMAN; SPLEEN; TH1 CELL; TH17 CELL; TUBERCULOSIS; VACCINATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; CELLULAR IMMUNITY; IMMUNIZATION; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-17; LECTINS; LIPID A; MICE, INBRED C57BL; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS; TH17 CELLS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84907979712     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.09.024     Document Type: Article

References (60)

1. World Health Organization Weekly epidemiological record 2011, 86:509-520. World Health Organization.
2. Colditz G.A., Berkey C.S., Mosteller F., Brewer T.F., Wilson M.E., Burdick E., et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995, 96:29-35.
3. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis-meta-analysis of the published literature. JAMA 1994, 271:698-702.
4. Ottenhoff T.H., Kaufmann S.H. Vaccines against tuberculosis: where are we and where do we need to go. PLoS Pathog 2012, 8(5):e1002607.
5. Kaufmann S.H. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol 2012, 33(7):373-379.
6. Brennan M.J., Stone M.R., Evans T. A rational vaccine pipeline for tuberculosis. Int J Tuberc Lung Dis 2012, 16(12):1566-1573.
7. Menozzi F.D., Rouse J.H., Alavi M., Laude-Sharp M., Muller J., Bischoff R., et al. Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med 1996, 184:993-1001.
8. Pethe K., Bifani P., Drobecq H., Sergheraert C., Debrie A.-S., Locht C., et al. Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. Proc Natl Acad Sci USA 2002, 99:10759-10764.
9. Pethe K., Alonso S., Biet F., Delogu G., Brennan M.J., Locht C., et al. The heparin-binding haemagglutinin of Mycobacterium tuberculosis is required for extrapulmonary dissemination. Nature 2001, 412:190-194.
10. Masungi C., Temmerman S., Van Vooren J.P., Drowart A., Pethe Menozzi F.D., et al. Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis 2002, 185:513-520.
11. Corbière V., Pottier G., Bonkain F., Schepers K., Verscheure V., Lecher S., et al. Risk stratification of latent tuberculosis defined by combined interferon gamma release assays. PLoS One 2012, 7:e43285.
12. Rouanet C., Debrie A.S., Lecher S., Locht C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 2009, 11:995-1001.
13. Parra M., Pickett T., Delogu G., Dheenadhayalan V., Debrie A-S., Locht C., et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 2004, 72:6799-6805.
14. Stephenson I., Zambon M.C., Rudin A., Colegate A., Podda A., Bugarini R., et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006, 80(10):4962-4970.
15. Chang J., Paillard A., Passirani C., Morille M., Benoit J.P., Betbeder D., et al. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res 2012, 29(6):1495-1505.
16. Paillard A., Passirani C., Saulnier P., Kroubi M., Garcion E., Benoit J.P., et al. Positively charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers. Pharm Res 2007, 27:126e33.
17. Dombu C., Carpentier R., Betbeder D. Influence of surface charge and inner composition of nanoparticles on intracellular delivery of proteins in airway epithelial cells. Biomaterials 2012, 33(Dec (35)):9117-9126.
18. Verwaerde C., Delanoye A., Macia L., Tailleux A., Wolowczuk I. Influence of high-fat feeding on both naive and antigen-experienced T-cell immune response in DO10.11 mice. Scand J Immunol 2006, 64(5):457-466.
19. Paget C., Ivanov S., Fontaine J., Blanc F., Pichavant M., Renneson J., et al. Potential role of invariant NKT cells in the control of pulmonary inflammation and CD8+ T cell response during acute influenza A virus H3N2 pneumonia. J Immunol 2011, 186(10):5590-5602.
20. Hartmann G., Weeratna R.D., Ballas Z.K., Payette P., Blackwell S., et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 2000, 164:1617-1624.
21. Al-Mariri A., Tibor A. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun 2001, 69(8):4816-4822.
22. Rhee E.G., Mendez S., Shah J.A., Wu C.Y., Kirman J.R., et al. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection. J Exp Med 2002, 195(12):1565-1573.
23. Taniguchi K., Takii T., Yamamoto S., Maeyama J., Iho S., Maruyama M., et al. Reactivation of immune responses against Mycobacterium tuberculosis by boosting with the CpG oligomer in aged mice primarily vaccinated with Mycobacterium bovis BCG. Immun Ageing 2013, 10(1):25.
24. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8(4):369-377.
25. Wozniak T.M., Saunders B.M., Ryan A.A., Britton W.J. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect Immun 2010, 78(10):4187-4194.
26. Lin Y., Slight S.R., Khader S.A. Th17 cytokines and vaccine induced immunity. Semin Immunopathol 2010, 32(1):79-90.
27. Dubin P.J., Kolls J.K. Th17 cytokines and mucosal immunity. Immunol Rev 2008, 226:160-171.
28. Zygmunt B.M., Rharbaoui F., Groebe L., Guzman C.A. Intranasal immunization promotes Th17 immune responses. J Immunol 2009, 183(11):6933-6938.
29. Kolls J.K., Khader S.A. The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev 2010, 6:443-448.
30. Menozzi F.D., Bischoff R., Fort E., Brennan M.J., Locht C. Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin. Proc Natl Acad Sci USA 1998, 95:12625-12630.
31. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neil C.P., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007, 25(10):1159-1164.
32. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38(5):1404-1413.
33. Debin A., Kravtzoff R., Vaz Santiago J., Cazales L., Sperandio S., Melber K., et al. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 2002, 20:2752-2763.
34. Malyala P., Chesko J., Ugozzoli M., Goodsell A., Zhou F., Vajdy M., et al. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci 2008, 97:1155-1164.
35. Fischer S., Schlosser E., Mueller M., Csaba N., Merkle H.P., Groettrup M., et al. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Target 2009, 17(8):652-661.
36. Krishnamachari Y., Salem A.K. Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev 2009, 61:205-217.
37. Wagner H. The immunogenicity of CpG-antigen conjugates. Adv Drug Deliv Rev 2009, 61:243-247.
38. Yamamoto S., Yamamoto T., Kataoka T., Kuramoto E., Yano O., Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural-killer activity. J Immunol 1992, 148(12):4072-4076.
39. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 1997, 27:2340-2344.
40. Klinman D.M., Currie D., Gursel I., Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004, 199(1):201-216.
41. Klinman D.M., Klaschik S., Sato T., Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009, 61:248-255.
42. McGeachy M.J., Cua D.J. Th17 cell differentiation: the long and winding road. Immunity 2008, 28(4):445-453.
43. Metwali A., Winckler S., Nedim Ince M., Elliott D.E. CpG oligonucleotide stimulation of TLR9 inhibits IL-17 production from mesenteric lymph node cells. Gastroenterology 2008, 134(4 (Suppl 1)):A-A651.
44. Chen L., Ahmed E., Wang T., Wang Y., Ochando J., Chong A.S., et al. TLR signals promote IL-6/IL-17-dependent transplant rejection. J Immunol 2009, 182(10):6217-6225.
45. Tigno-Aranjuez J.T., Jaime R., Tuohy V.K., Lehmann P.V., Tary-Lehmann M. Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells. J Immunol 2009, 183(9):5654-5661.
46. da Fonseca D.M., Silva C.L., Wowk P.F., Paula M.O., Ramos S.G., Horn C., et al. Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion. Infect Immun 2009, 77(12):5311-5321.
47. da Fonseca D.M., Silva C.L., Paula M.O., Soares E.G., Marchal G., Horn C., et al. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection. Immunology 2007, 121(4):508-517.
48. Ballester M., Nembrini C., Dhar N., de Titta A., de Piano C., Pasquier M., et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 2011, 29(40):6959-6966.
49. Todoroff J., Lemaire M.M., Fillee C., Jurion F., Renauld J.C., Huygen K., et al. Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice. PLoS One 2013, 8(5):e63344.
50. Xu L., Wang C., Zhou Y., Ren T., Wen Z. CpG oligonucleotides induce the differentiation of CD4(+)Th17 cells by triggering plasmacytoid dendritic cells in adoptively cell transfer immunotherapy. Immunol Lett 2012, 142(1-2):55-63.
51. Hoft D.F., Worku S., Kampmann B., et al. Investigation of the relationship between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis 2002, 186:1448-1457.
52. Cowley S.C., Elkins K.L. CD4+ T cells mediate IFN-γ-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J Immunol 2003, 171:4689-4699.
53. Abebe F. Is interferon-gamma the right marker for bacille Calmette-Guérin-induced immune protection? The missing link in our understanding of tuberculosis immunology. Clin Exp Immunol 2012, 169(3):213-219.
54. Okamoto Yoshida Y., Umemura M., Yahagi A., O'Brien R., Ikuta K., Kishihara K., et al. Essential role of IL-17A in the formation of a mycobacterial Infection induced granuloma in the lung. J Immunol 2010, 184:4414-4422.
55. Freches D., Korf H., Denis O., Havaux X., Huygen K., Romano M. Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection. Immunology 2013, 140(2):220-231.
56. Murphy KM1, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol 2010, 11(8):674-680.
57. Moseman EA1, Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004, 173(7):4433-4442.
58. LaRosa D.F., Gelman A.E., Rahman A.H., Zhang J., Turka L.A., et al. CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells. Immunol Lett 2007, 108(2):183-188.
59. Wu W1, Huang L., Mendez S. A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. Eur J Immunol 2010, 40(9):2517-2527.
60. Denis F., Alain S., Ploy M.C. New routes of administration: epidermal, transcutaneous mucosal ways of vaccination. Med Sci (Paris) 2007, 23(4):379-385.